Tuesday, 27 December 2011 08:12

Marken Appoints New Head Of Global Quality Assurance

Marken announced today that Steve Roese is named Vice President of Marken’s Global Quality Assurance organization, which will support Marken’s continued investment in their expanding network of pharmaceutical service depots around the world.

Marken is now accelerating construction of several new depot facilities in Europe, Asia and the US, which will supplement existing locations in Singapore, Mexico and Argentina.

Steve Roese comes to Marken with more than 30 years experience in quality operations at Wyeth Pharmaceuticals (now Pfizer) which included global operations in the consumer health and nutritional products divisions. He has extensive experience in both clinical and commercial manufacturing, packaging and distribution and has routinely interacted with the world’s most important regulatory agencies. Prior to Wyeth, Mr. Roese worked with Perrier / Nestle, Abbott Laboratories and General Foods in various quality and operations roles.

“We are excited to welcome Steve to the company”, commented Wes Wheeler, CEO of Marken. “Given our emphasis on clinical storage and distribution of drug product, Steve’s responsibilities will be a critically important priority for us. Quality has been, and will remain, a key part of our strategy in the future, and Steve’s experience in the pharma will enable us to take quality to a whole new level”.

About Marken
Marken is the leading global clinical supply chain service provider dedicated to the pharmaceutical and life sciences industries, supporting over 6,000 investigator sites in more than 100 countries. With decades of experience in the logistics, transport and distribution of temperature sensitive life saving pharmaceuticals, clinical trial supplies and specimen collection; Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naïve geographies. Our team members and network of facilities bridge the distance between patients and the essential resources of life science companies.

 

Read 624 times Last modified on Monday, 30 January 2012 10:18

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

Want more? Visit...

Videos

  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
    Read more...
  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
    Read more...
  • ERT- Partnerships 12
    ERT- Partnerships 12 John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
    Read more...
  • Chiltern- Partnerships 12
    Chiltern- Partnerships 12 Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
    Read more...
  • Blinded Diagnostics - Partnerships 12
    Blinded Diagnostics - Partnerships 12 Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
    Read more...
  • American Airlines - IQPC 2011
    American Airlines - IQPC 2011 American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.
    Read more...

Podcasts